Table 3 Clinicopathological features of PTMC cases with respect to BRAF and NRAS mutations.
Variables | BRAF mutation n (%) n = 54 | No BRAF mutation n (%) n = 21 | P-value | NRAS mutation n (%) n = 6 | No NRAS mutation n (%) n = 49 | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Age (years) | 0.42 | 0.88 | ||||||||
Mean ± SD | 46.6 ± 11.8 | 47.3 ± 14.9 | 45.0 ± 17.3 | 47.1 ± 11.6 | ||||||
Gender | 0.330 | 0.298 | ||||||||
Female | 43 | (79.6) | 19 | (90.5) | 4 | (66.7) | 41 | (83.7) | ||
Male | 11 | (20.4) | 2 | (9.5) | 2 | (33.3) | 8 | (16.3) | ||
Stage | 1.000 | 0.378 | ||||||||
I | 50 | (92.6) | 20 | (95.2) | 5 | (83.3) | 46 | (93.9) | ||
II | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
III | 3 | (5.6) | 1 | (4.8) | 1 | (16.7) | 2 | (4.1) | ||
IV | 1 | (1.9) | 0 | (0.0) | 0 | (0.0) | 1 | (2.0) | ||
Not available | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
Focality | 0.428 | 0.204 | ||||||||
Unifocal | 32 | (59.3) | 15 | (71.4) | 5 | (83.3) | 25 | (51.0) | ||
Multifocal | 22 | (40.7) | 6 | (28.6) | 1 | (16.7) | 24 | (49.0) | ||
Not available | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
Extrathyroidal extension | 1.000 | 0.619 | ||||||||
Present | 11 | (20.4) | 4 | (19.0) | 2 | (33.3) | 11 | (22.4) | ||
Absent | 43 | (79.6) | 17 | (81.0) | 4 | (66.7) | 38 | (77.6) | ||
Not available | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
Lymphovascular invasion | 0.850 | 0.339 | ||||||||
Present | 2 | (3.7) | 0 | (0.0) | 0 | (0.0) | 1 | (2.0) | ||
Absent | 46 | (85.2) | 18 | (85.7) | 4 | (66.7) | 41 | (83.7) | ||
Not available | 6 | (11.1) | 3 | (14.3) | 2 | (33.3) | 7 | (14.3) | ||
Lymphnodes status | 0.196 | 1.000 | ||||||||
Positive | 9 | (16.7) | 2 | (9.5) | 1 | (16.7) | 7 | (14.3) | ||
Negative | 14 | (25.9) | 2 | (9.5) | 1 | (16.7) | 13 | (26.5) | ||
Not available | 31 | (57.4) | 17 | (81.0) | 4 | (66.7) | 29 | (59.2) | ||
